Bcl-G polypeptides, encoding nucleic acids and methods of use
View Patent ↗The invention provides Bcl-G polypeptides and encoding nucleic acids. Bcl-G polypeptides include Bcl-G L and Bcl-G S . The invention also provides mouse Bcl-G. The invention also provides vectors containing Bcl-G nucleic acids, host cells containing such vectors, Bcl-G anti-sense nucleic acids and related compositions. The invention additionally provides Bcl-G oligonucleotides that can be used to hybridize to or amplify a Bcl-G nucleic acid. Anti-Bcl-G specific antibodies are also provided. Further provided are kits containing Bcl-G nucleic acids or Bcl-G specific antibodies. Such kits and reagents can be used to diagnose cancer, monitor response to therapy, or predict the prognosis of a cancer patient. The invention additionally provides methods of modulating apoptosis using Bcl-G polypeptides, encoding nucleic acids, or compounds that modulate the activity or expression of Bcl-G polypeptides. The methods for modulating apoptosis can be used to treat diseases such as cancer.
1. An isolated Bcl-G polypeptide, or a functional fragment thereof, comprising an amino acid sequence having at least 90% identity to SEQ ID NO:2, 4 or 42, wherein said polypeptide has Bcl-G functional activity.
2. The Bcl-G polypeptide of claim 1 , wherein said polypeptide has at least 95% identity to the amino acid sequence of Bcl-G L (SEQ ID NO:2), Bcl-G s (SEQ ID NO:4), or mouse Bcl-G (SEQ ID NO:42).
3. The Bcl-G polypeptide of claim 2 , wherein said polypeptide comprises the amino acid sequence of Bcl-G L (SEQ ID NO:2), Bcl-G s (SEQ ID NO:4), or mouse Bcl-G (SEQ ID NO:42).
4. The Bcl-G polypeptide of claim 1 , wherein said functional fragment comprises a BH3 or BH2 domain.
5. The Bcl-G polypeptide of claim 4 , wherein said functional fragment comprises an amino acid sequence selected from the group consisting of SEQ ID NOS:5, 6, 9 and 18.
6. A composition comprising a pharmaceutically acceptable carrier and the polypeptide of claim 1 .
7. The polypeptide of claim 1 , wherein the amino acid sequence has at least 90% identity to SEQ ID NO:2.
8. The polypeptide of claim 1 , wherein the amino acid sequence has at least 90% identity to SEQ ID NO:4.
9. The polypeptide of claim 1 , wherein the amino acid sequence has at least 90% identity to SEQ ID NO:42.
10. The polypeptide of claim 2 , wherein the amino acid sequence has at least 95% identity to SEQ ID NO:2.
11. The polypeptide of claim 2 , wherein the amino acid sequence has at least 95% identity to SEQ ID NO:4.
12. The polypeptide of claim 2 , wherein the amino acid sequence has at least 95% identity to SEQ ID NO:42.
13. The polypeptide of claim 3 , wherein the amino acid sequence comprises SEQ ID NO:2.
14. The polypeptide of claim 3 , wherein the amino acid sequence comprises SEQ ID NO:4.
15. The polypeptide of claim 3 , wherein the amino acid sequence comprises SEQ ID NO:42.
16. A composition comprising a pharmaceutically acceptable carrier and the polypeptide of claim 2 .
17. A composition comprising a pharmaceutically acceptable carrier and the polypeptide of claim 3 .
18. The polypeptide of claim 5 , wherein said functional fragment comprises the amino acid sequence of SEQ ID NO:5.
19. The polypeptide of claim 5 , wherein said functional fragment comprises the amino acid sequence of SEQ ID NO:6.
20. The polypeptide of claim 5 , wherein said functional fragment comprises the amino acid sequence of SEQ ID NO:9.
21. The polypeptide of claim 5 , wherein said functional fragment comprises the amino acid sequence of SEQ ID NO:18.